Bingxia Zhao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Bingxia Zhao has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
Zede Wu
Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China
11 shared publicationsQiuyu Li
Cancer Research Institute, School of Basic Medical Sciences, Southern Medical University, Guangzhou, 510515, China
10 shared publicationsShuting Zheng
Cancer Research Institute School of Basic Medical Sciences Southern Medical University Guangzhou China
10 shared publicationsYu Liang
Department of Medicine Ultrasound, Nanfang Hospital, Southern Medical University, Guangzhou, China
10 shared publications- Yikai Xu
Department of Medical Imaging Center, Nanfang Hospital, Southern Medical University, Guangzhou, China
9 shared publications Haibo Lan
Department of Medicine Ultrasonics, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, China
7 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Gold nanozyme-decorated Cu/Mn MOFs simultaneously enhances immunogenicity and alleviates immunosuppression in triple-negative breast cancer
Introduction: The efficacy of immunotherapy in triple-negative breast cancer (TNBC) is primarily challenged by its inherent low immunogenicity, which is further undermined by the immunosuppressive activity of tumor-associated polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). The hypoxic microenvironment renders PMN-MDSCs susceptible to ferroptosis and exacerbates immunosuppression. Objectives: This study aimed to design a multifunctional nanoplatform comprising Cu/Mn bimetallic metal-organic frameworks decorated with gold (Au) nanozymes (CMAP MOFs) that simultaneously enhances tumor immunogenicity and alleviates immunosuppression. Methods: The characteristics of the nanosystem were evaluated using transmission electron microscopy, X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy, and ultraviolet-visible spectrophotometry. In vitro experiments employed Western blotting, immunofluorescence, and flow cytometry to investigate the mechanisms of enhanced immunogenicity and alleviated immunosuppression in 4T1 cells. In vivo experiments evaluated the therapeutic efficacy of the nanosystem in BALB/c mice bearing implanted 4T1 tumors. Results: Within tumor cells, the CMAP MOFs undergo GSH-responsive disintegration. The released Cu/Mn ions catalyze Fenton-like reaction to induce tumor cell ferroptosis and mitochondrial DNA damage, activating cGAS-STING pathway, and facilitating CD8 + T cells recruitment. Simultaneously, released Au nanozymes catalyze H 2 O 2 conversion to O 2 , alleviating hypoxia and preventing PMN-MDSCs ferroptosis and associated immunosuppression. While the immunogenicity-enhancing CMP MOFs group increased CD8⁺ T cell infiltration from 21% to 28.3% with 74.1% tumor growth inhibition, the combined immunogenicity enhancement and immunosuppression relief CMAP MOFs group further boosted CD8⁺ T cell infiltration to 32.4% with superior tumor growth inhibition of 81.3%, with IFN-γ and GZMB expression elevated by 2.2-fold and 2.0-fold (CMP MOFs) and 3.4-fold and 3.0-fold (CMAP MOFs) compared to control. This strategy offers a promising approach for enhancing immunotherapy in TNBC patients.
- 25 April 2026
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessGold nanozyme-decorated Cu/Mn MOFs simultaneously enhances immunogenicity and alleviates immunosuppression in triple-negative breast cancer
Introduction: The efficacy of immunotherapy in triple-negative breast cancer (TNBC) is primarily challenged by its inherent low immunogenicity, which is further undermined by the immunosuppressive activity of tumor-associated polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs). The hypoxic microenvironment renders PMN-MDSCs susceptible to ferroptosis and exacerbates immunosuppression. Objectives: This study aimed to design a multifunctional nanoplatform comprising Cu/Mn bimetallic metal-organic frameworks decorated with gold (Au) nanozymes (CMAP MOFs) that simultaneously enhances tumor immunogenicity and alleviates immunosuppression. Methods: The characteristics of the nanosystem were evaluated using transmission electron microscopy, X-ray photoelectron spectroscopy, Fourier transform infrared spectroscopy, and ultraviolet-visible spectrophotometry. In vitro experiments employed Western blotting, immunofluorescence, and flow cytometry to investigate the mechanisms of enhanced immunogenicity and alleviated immunosuppression in 4T1 cells. In vivo experiments evaluated the therapeutic efficacy of the nanosystem in BALB/c mice bearing implanted 4T1 tumors. Results: Within tumor cells, the CMAP MOFs undergo GSH-responsive disintegration. The released Cu/Mn ions catalyze Fenton-like reaction to induce tumor cell ferroptosis and mitochondrial DNA damage, activating cGAS-STING pathway, and facilitating CD8 + T cells recruitment. Simultaneously, released Au nanozymes catalyze H 2 O 2 conversion to O 2 , alleviating hypoxia and preventing PMN-MDSCs ferroptosis and associated immunosuppression. While the immunogenicity-enhancing CMP MOFs group increased CD8⁺ T cell infiltration from 21% to 28.3% with 74.1% tumor growth inhibition, the combined immunogenicity enhancement and immunosuppression relief CMAP MOFs group further boosted CD8⁺ T cell infiltration to 32.4% with superior tumor growth inhibition of 81.3%, with IFN-γ and GZMB expression elevated by 2.2-fold and 2.0-fold (CMP MOFs) and 3.4-fold and 3.0-fold (CMAP MOFs) compared to control. This strategy offers a promising approach for enhancing immunotherapy in TNBC patients.
- 21 January 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (33)
Quantity‐Quality Dual‐Regulation Strategy: Enzyme‐Like Nanoclusters for Improved Cancer Immunotherapy
Cancer immunotherapy faces significant challenges in breast cancer treatment. Cuproptosis‐triggered immunogenic cell death (ICD) offers a novel strategy for tumor immunotherapy. However, its clinical application encounters two significant challenges. Firstly, the immune activator ATP released during ICD process is converted into immunosuppressive adenosine (ADO) within tumor microenvironment (TME) through the CD39/CD73 exonucleosidase cascade reaction. Secondly, T cells isolated by bone marrow restrict the infiltration of effector T cells into tumors. To address these, we designed enzyme‐like Au‐SS‐Cu@PEG nanoclusters (ACSP NCs) for a “cuproptosis‐ATP/ADO metabolic reprogramming‐T cell chemotaxis” cascade amplification strategy. Upon accumulation within TME, ACSP NCs release Cu 2 + to trigger cuproptosis and ICD, inducing ATP release for dendritic cells (DC) maturation. Furthermore, ACSP NCs exhibit enzyme‐like activity, alleviating tumor hypoxia and downregulating CD39/CD73 expression, reducing ADO levels to 30% of the control group. To achieve systemic immune activation, paroxetine (PX) co‐administration targets the S1P/S1PR1 axis, disrupting the bone marrow retention, thereby increasing T cell populations within the lymphatic circulation, and significantly enhancing tumor infiltration of CD8 + T cells. By combining both “Quantity Regulation” (increased T cell quantity) and “Quality Regulation” (activated T cell function) within the TME, our approach provides a powerful approach for overcoming immune suppression and boosting cancer immunotherapy.
- 21 January 2026
- Published by Wiley in Advanced Functional Materials
- Vol. 36 (33)
Quantity‐Quality Dual‐Regulation Strategy: Enzyme‐Like Nanoclusters for Improved Cancer Immunotherapy
Cancer immunotherapy faces significant challenges in breast cancer treatment. Cuproptosis‐triggered immunogenic cell death (ICD) offers a novel strategy for tumor immunotherapy. However, its clinical application encounters two significant challenges. Firstly, the immune activator ATP released during ICD process is converted into immunosuppressive adenosine (ADO) within tumor microenvironment (TME) through the CD39/CD73 exonucleosidase cascade reaction. Secondly, T cells isolated by bone marrow restrict the infiltration of effector T cells into tumors. To address these, we designed enzyme‐like Au‐SS‐Cu@PEG nanoclusters (ACSP NCs) for a “cuproptosis‐ATP/ADO metabolic reprogramming‐T cell chemotaxis” cascade amplification strategy. Upon accumulation within TME, ACSP NCs release Cu 2 + to trigger cuproptosis and ICD, inducing ATP release for dendritic cells (DC) maturation. Furthermore, ACSP NCs exhibit enzyme‐like activity, alleviating tumor hypoxia and downregulating CD39/CD73 expression, reducing ADO levels to 30% of the control group. To achieve systemic immune activation, paroxetine (PX) co‐administration targets the S1P/S1PR1 axis, disrupting the bone marrow retention, thereby increasing T cell populations within the lymphatic circulation, and significantly enhancing tumor infiltration of CD8 + T cells. By combining both “Quantity Regulation” (increased T cell quantity) and “Quality Regulation” (activated T cell function) within the TME, our approach provides a powerful approach for overcoming immune suppression and boosting cancer immunotherapy.
- Open Access
- 17 December 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Low-intensity pulsed ultrasound (LIPUS)-augmented calcicoptosis by calcium-based nanoparticles for enhanced immunogenic cell death induction in triple-negative breast cancer
Triple-negative breast cancer (TNBC) shows limited therapeutic efficacy due to the absence of effective targeted treatment options, with its immunosuppress
- 17 December 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 24 (1)
Open AccessLow-intensity pulsed ultrasound (LIPUS)-augmented calcicoptosis by calcium-based nanoparticles for enhanced immunogenic cell death induction in triple-negative breast cancer
Triple-negative breast cancer (TNBC) shows limited therapeutic efficacy due to the absence of effective targeted treatment options, with its immunosuppress
- Open Access
- 25 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 737
Ion-interference amplifier nano-system enhances radiotherapy via mitochondrial dysfunction and efferocytosis Inhibition
The efficacy of radiotherapy (RT) is often compromised by tumor radioresistance and an immunosuppressive microenvironment. Two key limitations are the clea
- 25 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 737
Open AccessIon-interference amplifier nano-system enhances radiotherapy via mitochondrial dysfunction and efferocytosis Inhibition
The efficacy of radiotherapy (RT) is often compromised by tumor radioresistance and an immunosuppressive microenvironment. Two key limitations are the clea
- RetractedOpen Access
- 5 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-2
Retraction Note: Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) Paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP)
- 5 November 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-2
RetractedOpen AccessRetraction Note: Graphene oxide (GO)-based nanosheets with combined chemo/photothermal/photodynamic therapy to overcome gastric cancer (GC) Paclitaxel resistance by reducing mitochondria-derived adenosine-triphosphate (ATP)
- 30 July 2025
- Published by Elsevier in Biomaterials
- Vol. 325, 123592
Copper metal-organic framework-based multifaceted strategy for boosting cancer therapy via synergistic cuproptosis and disulfidptosis
- 30 July 2025
- Published by Elsevier in Biomaterials
- Vol. 325, 123592
Copper metal-organic framework-based multifaceted strategy for boosting cancer therapy via synergistic cuproptosis and disulfidptosis
- Open Access
- 21 July 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-16
Multifunctional nanoagent for enhanced cancer radioimmunotherapy via pyroptosis and cGAS-STING activation
The immunosuppressive tumor microenvironment (ITME) and inherent radioresistance of tumor cells limit the effectiveness of radioimmunotherapy and exacerbate immune evasion. To address these challenges, PEGylated Azacitidine-loaded and Mn2+-doped calcium carbonate nanoparticles (A@MCP NPs) are synthesized as multifunctional nanoagent to enhance radioimmunotherapy outcomes. Upon acidic TME, the release of Ca2+ and Mn2+ from A@MCP NPs co-triggers intracellular reactive oxygen species (ROS) generation via Ca2+ overload and Fenton-like reactions, inducing cytochrome C release and caspase-3 activation. Concurrently, released Azacitidine inhibits DNA methylation, upregulating GSDME expression in irradiated tumor cells, which synergistically amplifies caspase-3/GSDME-induced pyroptosis. The resulting pyroptotic cell damage, coupled with radiotherapy (RT)-induced DNA, activates Mn2+-sensitized cGAS-STING pathways, amplifying immune responses. Collectively, A@MCP, as a nano radiosensitizer, together with RT, co-activates pyroptosis and cGAS-STING to further amplify anti-tumor immune response, overcome ITME-mediated resistance and offer significant potential for improved cancer radioimmunotherapy.
- 21 July 2025
- Published by Springer Nature in Journal of Nanobiotechnology
- Vol. 23 (1) , 1-16
Open AccessMultifunctional nanoagent for enhanced cancer radioimmunotherapy via pyroptosis and cGAS-STING activation
The immunosuppressive tumor microenvironment (ITME) and inherent radioresistance of tumor cells limit the effectiveness of radioimmunotherapy and exacerbate immune evasion. To address these challenges, PEGylated Azacitidine-loaded and Mn2+-doped calcium carbonate nanoparticles (A@MCP NPs) are synthesized as multifunctional nanoagent to enhance radioimmunotherapy outcomes. Upon acidic TME, the release of Ca2+ and Mn2+ from A@MCP NPs co-triggers intracellular reactive oxygen species (ROS) generation via Ca2+ overload and Fenton-like reactions, inducing cytochrome C release and caspase-3 activation. Concurrently, released Azacitidine inhibits DNA methylation, upregulating GSDME expression in irradiated tumor cells, which synergistically amplifies caspase-3/GSDME-induced pyroptosis. The resulting pyroptotic cell damage, coupled with radiotherapy (RT)-induced DNA, activates Mn2+-sensitized cGAS-STING pathways, amplifying immune responses. Collectively, A@MCP, as a nano radiosensitizer, together with RT, co-activates pyroptosis and cGAS-STING to further amplify anti-tumor immune response, overcome ITME-mediated resistance and offer significant potential for improved cancer radioimmunotherapy.
- Open Access
- 26 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (36) , e04252
Nanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation
The cGAS‐STING signaling pathway has emerged as a promising target for cancer immunotherapy. However, STING agonists have a dual‐edged nature. Although they enhance antitumor T cell activity, STING agonists also elicit protumorigenic effects by promoting IL‐35‐producing B regulatory (Breg) cells, suppressing natural killer (NK) cell density, and fostering immune suppression. To address these challenges, this work develops a tumor microenvironment‐responsive hollow mesoporous nanosystem that degrades under high glutathione conditions, thereby releasing the STING agonist MSA‐2 and Mn ions. This nanosystem facilitates magnetic resonance imaging‐guided chemodynamic therapy and radiosensitization, efficiently activating the cGAS‐STING pathway by disrupting mitochondrial and nuclear DNA. Notably, by integrating this nanosystem with an anti‐IL‐35 blockade, this work successfully mitigates the Breg cell‐mediated suppression of NK cells, restores innate immune responses, and enhances antitumor efficacy. This study highlights the pivotal role of anti‐IL‐35 in reversing immunosuppression, enhancing innate immunity, and establishing a synergistic theranostic platform for molecular imaging‐guided cancer radioimmunotherapy.
- 26 June 2025
- Published by Wiley in Advanced Science
- Vol. 12 (36) , e04252
Open AccessNanosensitizer for Cancer Radioimmunotherapy via Anti‐IL‐35 Blockade Boosted Innate Immunity Activation
The cGAS‐STING signaling pathway has emerged as a promising target for cancer immunotherapy. However, STING agonists have a dual‐edged nature. Although they enhance antitumor T cell activity, STING agonists also elicit protumorigenic effects by promoting IL‐35‐producing B regulatory (Breg) cells, suppressing natural killer (NK) cell density, and fostering immune suppression. To address these challenges, this work develops a tumor microenvironment‐responsive hollow mesoporous nanosystem that degrades under high glutathione conditions, thereby releasing the STING agonist MSA‐2 and Mn ions. This nanosystem facilitates magnetic resonance imaging‐guided chemodynamic therapy and radiosensitization, efficiently activating the cGAS‐STING pathway by disrupting mitochondrial and nuclear DNA. Notably, by integrating this nanosystem with an anti‐IL‐35 blockade, this work successfully mitigates the Breg cell‐mediated suppression of NK cells, restores innate immune responses, and enhances antitumor efficacy. This study highlights the pivotal role of anti‐IL‐35 in reversing immunosuppression, enhancing innate immunity, and establishing a synergistic theranostic platform for molecular imaging‐guided cancer radioimmunotherapy.
- Open Access
- 31 March 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 79, 905-916
Exploiting metabolic vulnerabilities through synergistic ferroptosis and disulfidptosis for breast cancer therapy
- 31 March 2025
- Published by Elsevier in Journal of Advanced Research
- Vol. 79, 905-916
Open AccessExploiting metabolic vulnerabilities through synergistic ferroptosis and disulfidptosis for breast cancer therapy
Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery
Biomimetic camouflaged nanocarriers coated with cancer cell membranes (CCMs) have attracted considerable research attention for drug delivery application. CCM‐camouflaged nanocarriers have inherent tumor‐homologous targeting ability. However, they enter cancer cells via endocytosis, which is not efficient for drug delivery. Switching the internalization mechanism to membrane fusion may enhance their delivery efficiency. In this study, an innovative biomimetic‐targeting nanocarrier is designed by hybridizing CCMs with pH‐sensitive liposomes (1,2‐dioleoyl‐sn‐glycero‐3‐phosphoethanolamine liposomes, DOPE‐Lipo), named as CCMpHD. The presence of CCMs makes the nanocarriers capable of homologous targeting, and the DOPE‐Lipo hybrid allows the nanocarriers to achieve efficient internalization via membrane fusion. Notably, the cellular uptake of CCMpHD is significantly higher than that of the CCMs. The most efficient delivery is achieved with 1/10 CCMs, which requires remarkably less cell membranes. Doxorubicin (DOX) is used as a model drug to characterize the homologous targeting drug delivery properties of the hybrid nanocarriers. Both in vitro and in vivo experiments demonstrated that the nanocarriers exhibited satisfactory biosafety and enhanced tumor‐targeted delivery. With enhanced delivery efficiency whilst requiring fewer CCMs, these hybrid membrane nanocarriers provides a new strategy for CCM‐based drug delivery in cancer treatment.
Less is More: Biomimetic Hybrid Membrane Nanocarriers for Highly Efficient Tumor Targeted Drug Delivery
Biomimetic camouflaged nanocarriers coated with cancer cell membranes (CCMs) have attracted considerable research attention for drug delivery application. CCM‐camouflaged nanocarriers have inherent tumor‐homologous targeting ability. However, they enter cancer cells via endocytosis, which is not efficient for drug delivery. Switching the internalization mechanism to membrane fusion may enhance their delivery efficiency. In this study, an innovative biomimetic‐targeting nanocarrier is designed by hybridizing CCMs with pH‐sensitive liposomes (1,2‐dioleoyl‐sn‐glycero‐3‐phosphoethanolamine liposomes, DOPE‐Lipo), named as CCMpHD. The presence of CCMs makes the nanocarriers capable of homologous targeting, and the DOPE‐Lipo hybrid allows the nanocarriers to achieve efficient internalization via membrane fusion. Notably, the cellular uptake of CCMpHD is significantly higher than that of the CCMs. The most efficient delivery is achieved with 1/10 CCMs, which requires remarkably less cell membranes. Doxorubicin (DOX) is used as a model drug to characterize the homologous targeting drug delivery properties of the hybrid nanocarriers. Both in vitro and in vivo experiments demonstrated that the nanocarriers exhibited satisfactory biosafety and enhanced tumor‐targeted delivery. With enhanced delivery efficiency whilst requiring fewer CCMs, these hybrid membrane nanocarriers provides a new strategy for CCM‐based drug delivery in cancer treatment.